Aardvark Therapeutics, Inc. Common Stock (AARD NASDAQ) stock market data APIs
$6.0627
-0.36(-5.9%)
as of March 9, 2026
Try our APIs with
free plan!
Aardvark Therapeutics, Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen, which is in the Phase 3 clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in the Phase 2 clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from the treatment of craniopharyngioma, including surgery or radiation. The company is also developing ARD-201, which is in the Phase 1 clinical trial for the treatment of obesity. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Prev. Close
6.0627
Open
5.6992
High
6.2181
Low
5.684
52 wk Range
4.74-17.94
Market Cap
127 M
Shares Outstanding
21 773 K
EPS
-0.75
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Aardvark Therapeutics, Inc. Common Stock (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Aardvark Therapeutics, Inc. Common Stock data using free add-ons & libraries
Get Aardvark Therapeutics, Inc. Common Stock Fundamental Data
Aardvark Therapeutics, Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -53 437 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-13
- EPS/Forecast: -0.77
Get Aardvark Therapeutics, Inc. Common Stock End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Aardvark Therapeutics, Inc. Common Stock News
New
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) (NASDAQ: AARD). Such in...
Sector Update: Health Care Stocks Retreat Late Afternoon
Health care stocks declined late Monday afternoon with the NYSE Health Care Index falling 1.2% and t PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Aardvark Therapeutics Pauses Phase 3 Trial Of ARD-101 In Prader-Willi Syndrome; Stock Plunges
(RTTNews) - Aardvark Therapeutics Inc. (AARD) announced that it has voluntarily paused the Phase 3 Hunger Elimination or Reduction Objective (HERO) trial. The HERO study is a randomized, double-blind,...
Aardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi Syndrome
SAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutic...
Get Aardvark Therapeutics, Inc. Common Stock fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
